5 ESSENTIAL ELEMENTS FOR ABBV-744 DRUG DEVELOPMENT PROGRESS AND TIMELINE

In Section C, members will receive ABBV-744 and oral navitoclax. In Segment D, individuals will acquire ABBV-744 and ruxolitinib. Participants will get treatment right up until condition progression or maybe the participants are not able to tolerate the study drugs.then promote H3K27Ac at this area. Chromatin hyperacetylation could increase the acc